Sir, In 2008, the alarming level of antibiotic resistance in France led us to release regional guidelines for the treatment of urinary tract infections (UTIs). 1 Briefly, we recommended (i) the avoidance of fluoroquinolones for uncomplicated UTIs and (ii) the use of fosfomycin (single 3 g dose) or nitrofurantoin (100 mg three times a day, 5 days) as first-line treatment. Accordingly, fosfomycin and nitrofurantoin prescriptions increased, while fluoroquinolone prescriptions declined. 2 In February 2011, the French Agency for the Safety of Medicine and Health Products (ANSM) published a drug monitoring alert concerning nitrofurantoin. 3 This letter reported new cases of severe hepatic and pulmonary toxicity after prolonged treatments with nitrofurantoin. National guidelines were suspended, while nitrofurantoin's use as prophylaxis for UTIs was strongly discouraged. One year later the ANSM issued its new guidelines, stating that: (i) nitrofurantoin is responsible for severe pulmonary and hepatic toxicity; (ii) nitrofurantoin should be used for documented cystitis due to susceptible microorganisms only when no other antimicrobial presenting a better benefit/risk ratio can be used orally; (iii) nitrofurantoin can nevertheless be considered for empirical treatment in cases of urgency or in the setting of a previous history of multidrug-resistant bacteria; and (iv) nitrofurantoin must not be used as prophylaxis.
We assessed the impact of the ANSM guidelines on drugs prescribed for UTIs in our region using antibiotic prescription data (nitrofurantoin, fosfomycin and fluoroquinolones with the exception of anti-pneumococcal fluoroquinolones) extracted from the region's health insurance agency (ambulatory care for women aged 15 -65 years). Antibiotic consumption was measured from May 2007 to August 2012 via monthly totals of daily defined doses (DDDs) according to WHO recommendations. 4 The publication of the drug monitoring alert led to a prompt and significant (P,0.001) decrease in nitrofurantoin use: the relative variation was 249.3% 16 months after the release ( Figure 1 ). We also observed a significant increase in 3 day fluoroquinolone treatment packs (lomefloxacin), single-dose fluoroquinolone packs (ofloxacin or ciprofloxacin) and multi-dose ofloxacin packs. Throughout the entire study period, the consumption of fosfomycin increased, that of ciprofloxacin was stable and that of norfloxacin decreased, with no change in trend (Figure 1 ). Our dataset did not allow the tracing of indications for nitrofurantoin prescriptions (i.e. short-term use versus prophylaxis or intermittent use). However, a French global prescription survey suggests that 75% of nitrofurantoin is prescribed for short-term treatments. 5 It is thus very likely that the two-to-one reduction in nitrofurantoin use in our region is not only linked to the ban on nitrofurantoin for UTI prophylaxis but has also impacted short-term use. For the latter, prescribers largely replaced nitrofurantoin with fluoroquinolones.
The alert was the consequence of a survey of nitrofurantoin's adverse effects: the French Committee on Drug Monitoring reported severe adverse effects, mainly pulmonary or hepatic, with a frequency of 12.7 per year (1 per 20 551 nitrofurantoin prescriptions). 5 This frequency increased with treatment duration: from 1 case per 24 800 short-term prescriptions (,1 month) to 1 case per 7666 long-term prescriptions (.1 month). In addition, the context of this alert must be taken into account. It was issued shortly after the French medical community had been rocked by the Mediator scandal, which appeared to some to expose the French pharmaceutical oversight apparatus as relatively permissive, if not lax. 6 To our knowledge, no other European country has released similar recommendations, while most of them use more nitrofurantoin than France, including for recurrent UTIs. 7 According to most European experts' analyses, there is no strong scientific evidence to limit the use of nitrofurantoin for both incident and recurrent short-term UTI treatment, and its use is now recommended in numerous guidelines worldwide. 8 The incidence of serious adverse events due to antibiotic classes deserves scrutiny. A survey led by the CDC estimated nearly identical incidence rates in emergency department visits triggered by nitrofurantoin and quinolone use (9.8 versus 9.2 visits per 10000 outpatient prescriptions, respectively); the study aggregated data for short-and long-term nitrofurantoin therapy. 9 From our point of view, the unfortunate phrasing of new French guidelines left virtually no room for nitrofurantoin in UTIs, given that cultures are not routinely collected and thus true infection is rarely documented in women presenting with symptoms of UTI.
In conclusion, while long-term, prophylactic nitrofurantoin should be restricted, we believe that nitrofurantoin should retain its place in the therapeutic armamentarium for UTIs, especially in the face of rising multidrug-resistant Enterobacteriaceae. The tremendous impact of increased fluoroquinolone consumption on antimicrobial resistance has been well documented. 10 In the setting of rapidly increasing antimicrobial resistance and an alarming paucity of novel therapeutic options, it is imperative that policy makers avoid reactionary measures and take instead the long view. 
